BofA cuts Vertex target to USD 667 for Vertex Pharmaceuticals stock

Published on 10/20/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BofA cut its target to USD 667 on October 12, 2026. Vertex Pharmaceuticals stock stands at EUR 449.60 on October 20, 2026, valued at USD 127.2 billion.

Targets and reporting dates

BofA Securities lowered its Vertex target from USD 672 to USD 667 on October 12, 2026.
Vertex Pharmaceuticals will report third-quarter 2026 results on November 2, 2026.
Vertex Pharmaceuticals stock trades at EUR 449.60 at 11:03 a.m. CEST at Lang & Schwarz on October 20, 2026.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin am Mikroskop im Labor — Vertex Pharma US92532F1003 dokumentiert eine Forscherin beim Mikroskopieren in dokumentarischer Schwarzweiß-Reportage-Optik im Labor, Illustration mit AI erstellt.

Vertex Pharmaceuticals (US92532F1003) stock stood at EUR 449.60 at Lang & Schwarz on October 20, 2026, at 11:03 a.m. CEST. The latest analyst action came from BofA Securities, which lowered its price target from USD 672 to USD 667 on October 12, 2026, while maintaining a Buy rating, according to Investing.com.

BofA trims target to USD 667

The target reduction was tied to BofA's outlook for Vertex's cystic fibrosis franchise and upcoming product contributions. The analyst expects third-quarter revenue of USD 2.42 billion for Trikafta, compared with a USD 2.54 billion consensus estimate, while projecting USD 688 million from Alyftrek against a USD 651 million consensus estimate, Investing.com reported on October 12, 2026.

BofA also cited Vertex's raised fiscal 2026 revenue guidance of USD 13.1 billion to USD 13.2 billion. That range gives investors a concrete test for the November results, particularly as newer medicines expand beyond the company's established cystic fibrosis business.

What will November results test?

Vertex will report its third-quarter 2026 financial results after the market close on November 2, 2026, and will hold its earnings call at 4:30 p.m. ET, according to the company's release dated October 7, 2026. The announcement identifies Vertex as a Nasdaq-listed company with the ticker VRTX, Vertex Pharmaceuticals said.

The company enters that reporting date with a USD 127.2 billion market capitalization as of October 19, 2026. Its quoted 52-week range runs from USD 403.16 to USD 560.25, putting the latest US market reference below the upper end of that span. The range and market capitalization are separate US-dollar context figures, not substitutes for the euro reference price.

Vertex stock and the next catalyst

For investors, the key question is whether the September quarter supports the higher revenue outlook while Alyftrek, Casgevy and Journavx contribute more meaningfully. BofA's estimates put quarterly revenue at USD 83 million for Casgevy and USD 68 million for Journavx, with the latter forecast above a USD 65 million consensus estimate, Investing.com reported.

Euro quote on October 20

Vertex Pharmaceuticals stock was trading at EUR 449.60 at Lang & Schwarz on October 20, 2026, at 11:03 a.m. CEST. The next dated company event is the third-quarter results release on November 2, 2026, after the market close. The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.